Specialty pharmaceutical company that manufactures generic, brand and biologic drugs
H.R. 6433, the "FDA User Fee Corrections Act of 2012," which amends the Food and Drug Administration Safety and Innovation Act (Public Law 112-144) to make technical changes to both the generic drug user fee program and the medical device user fee program;

Monitoring the impact of sequestration on FDA funding 

Monitoring supply chain safety
HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE
LOPER CONSULTING LLC
4551 32nd Road North, Arlington, VA, 22207, US
GINGER LOPER (Special Assistant to the President (2002-2005))
Special Assistant to the President (2002-2005)